Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma
出版年份 2012 全文链接
标题
Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma
作者
关键词
-
出版物
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 37, Issue 1, Pages 62-73
出版商
Wiley
发表日期
2012-11-08
DOI
10.1111/apt.12132
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Potentially curative treatment in patients with hepatocellular cancer-results from the liver cancer research network
- (2012) F. Kanwal et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2012) EUROPEAN JOURNAL OF CANCER
- Hepatocellular carcinoma
- (2012) Alejandro Forner et al. LANCET
- Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
- (2011) Andrew X. Zhu et al. CANCER
- Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy
- (2011) Chiao-Fang Teng et al. HEPATOLOGY
- Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis
- (2011) Wenhua Liang et al. LIVER TRANSPLANTATION
- Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
- (2011) A.-C. Piguet et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Calcineurin Inhibitor-free Immunosuppression Using Everolimus (Certican) after Heart Transplantation: 2 years' Follow-up from the University Hospital Münster
- (2011) J. Stypmann et al. TRANSPLANTATION PROCEEDINGS
- Pilot study: rapamycin in advanced hepatocellular carcinoma
- (2010) M. Schöniger-Hekele et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Reactivation of hepatitis B
- (2010) Jay H. Hoofnagle HEPATOLOGY
- Hepatitis B virus genotyping by enzyme-linked immunosorbent assay in Taiwan
- (2010) Shu-Fen Liu et al. Hepatology International
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
- (2009) I. Okamoto et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
- (2008) Augusto Villanueva et al. GASTROENTEROLOGY
- Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer
- (2008) Magnus Rizell et al. International Journal of Clinical Oncology
- RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
- (2008) Hung Huynh et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- (2008) Anne O'Donnell et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now